Next-generation gemcitabine prodrugs: Overcoming biological barriers through chemical innovation

Gemcitabine (GEM) remains a cornerstone in the treatment of solid tumours. However, its clinical efficacy is limited by rapid metabolic inactivation by cytidine deaminase (CDA), dependence on nucleoside transporters (hENT1), and inefficient intracellular activation. This review addresses the "gemcitabine paradox", highlighting how increasing chemical sophistication has been deployed to overcome these biological barriers. We examine prodrug design strategies primarily targeting the 4-N and 5'-O positions. 4-N modifications aim to protect GEM from systemic deamination, whereas 5'-O derivatives, particularly ProTide-based approaches, bypass transporter dependence and the rate-limiting initial phosphorylation step. Emerging next-generation systems further exploit tumour-specific triggers-such as hypoxia, reactive oxygen species (ROS), H₂S, and enzyme-mediated activation-as well as bioorthogonal chemistry to achieve spatiotemporally controlled drug release. The development of theranostic agents and multitarget co-drugs also reflects a shift toward precision medicine. Despite promising preclinical outcomes, translation to the clinic remains challenging, as illustrated by recent failures of NUC-1031 and CP-4126. This review underscores the need for improved in vivo validation and optimization of physicochemical properties, particularly aqueous solubility, to convert chemical innovation into tangible therapeutic benefit.